Investment Thesis
Boston Scientific demonstrates impressive revenue growth (+19.9% YoY) and excellent profit margins (69.5% gross, 25.8% net), indicating strong market position in medical devices. However, a severe disconnect between reported net income and free cash flow (3.3% FCF margin vs 25.8% net margin), combined with weak ROE/ROA metrics, raises significant concerns about earnings quality and capital efficiency despite manageable debt levels.
Strengths
- Strong topline growth at 19.9% YoY revenue increase
- Exceptional net margin of 25.8% and gross margin of 69.5% demonstrating pricing power and cost control
- Solid debt service capability with 12.2x interest coverage and moderate 0.42x debt-to-equity ratio
- Healthy liquidity position with 1.90x current ratio and $1.5B cash
Risks
- Severe cash flow conversion problem: 25.8% net margin but only 3.3% FCF margin indicates working capital stress or quality of earnings concerns
- Poor return metrics with ROE of only 5.2% and ROA of 3.0% despite high profitability margins
- Net income growth of only 0.2% YoY dramatically underperforms revenue growth, suggesting margin compression or significant non-operating charges
- Substantial $11.0B debt load creating financial leverage; low FCF generation limits debt reduction capacity
- Significant gap between operating income ($1.1B) and operating cash flow ($348M) suggests asset-heavy operations with poor cash yields
Key Metrics to Watch
- Free cash flow trend and FCF margin expansion toward revenue growth rates
- Return on equity and return on assets improvement trajectory
- Operating cash flow relative to operating income; investigate working capital movements
- Debt reduction progress and interest expense management
- Revenue growth sustainability and whether it converts to proportional net income growth
Financial Metrics
Revenue
5.2B
Net Income
1.3B
EPS (Diluted)
$0.90
Free Cash Flow
171.0M
Total Assets
44.4B
Cash
1.5B
Profitability Ratios
Gross Margin
69.5%
Operating Margin
21.2%
Net Margin
25.8%
ROE
5.2%
ROA
3.0%
FCF Margin
3.3%
Balance Sheet & Liquidity
Current Ratio
1.90x
Quick Ratio
1.22x
Debt/Equity
0.42x
Debt/Assets
0.0%
Interest Coverage
12.23x
Long-term Debt
11.0B
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T11:15:54.370935 |
Data as of: 2026-03-31 |
Powered by Claude AI